aod9604 stimulates lipolysis adipocytes AOD-9604 10mg Regulation of lipolysis in adipocytes

Drugs that activate dopamine receptors can decrease alcohol consumption, while those that block the receptors tend to have the opposite effect

Inhibit osteoclast activation and differentiation, reduce bone resorption Block osteoclast differentiation signal RANKL/RANK/OPG pathway: AOD 9604 downregulates the expression of RANKL (a key factor in osteoclast differentiation) and upregulates the expression of OPG (a RANKL antagonist), reducing the RANKL/OPG ratio by 50-60% and blocking the differentiation of osteoclast precursors into mature osteoclasts

Third, constipation and diarrhea, which represent opposing effects on bowel function, both increased with orforglipron treatment, reflecting the complex effects of GLP-1 receptor activation on gut motility, water absorption, and intestinal secretion

4 weeks OFF AOD-9604 Anti-Obesity Drug (AOD) 9604